Wedbush Securities Inc. reduced its stake in bluebird bio (NASDAQ:BLUE) by 29.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,300 shares of the biotechnology company’s stock after selling 950 shares during the quarter. Wedbush Securities Inc.’s holdings in bluebird bio were worth $393,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Dimensional Fund Advisors LP lifted its stake in bluebird bio by 31.8% in the third quarter. Dimensional Fund Advisors LP now owns 139,994 shares of the biotechnology company’s stock valued at $19,231,000 after buying an additional 33,805 shares during the period. Creative Planning acquired a new position in bluebird bio in the fourth quarter valued at approximately $323,000. Schwab Charles Investment Management Inc. lifted its stake in bluebird bio by 11.0% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 296,073 shares of the biotechnology company’s stock valued at $52,731,000 after buying an additional 29,380 shares during the period. Westpac Banking Corp lifted its stake in bluebird bio by 20.9% in the fourth quarter. Westpac Banking Corp now owns 33,592 shares of the biotechnology company’s stock valued at $5,983,000 after buying an additional 5,800 shares during the period. Finally, Steward Partners Investment Advisory LLC lifted its stake in bluebird bio by 758.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,716 shares of the biotechnology company’s stock valued at $305,000 after buying an additional 1,516 shares during the period.
Several equities analysts have issued reports on BLUE shares. Cantor Fitzgerald dropped their price target on bluebird bio from $122.00 to $113.00 and set an “underweight” rating on the stock in a research note on Thursday, February 22nd. ValuEngine raised bluebird bio from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. BTIG Research reaffirmed a “buy” rating on shares of bluebird bio in a research report on Thursday, May 3rd. BidaskClub lowered bluebird bio from a “hold” rating to a “sell” rating in a research report on Wednesday, April 4th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and set a $194.00 target price (down from $211.00) on shares of bluebird bio in a research report on Monday. Four research analysts have rated the stock with a sell rating, nine have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. bluebird bio has a consensus rating of “Hold” and a consensus target price of $194.50.
Shares of bluebird bio stock opened at $174.40 on Tuesday. bluebird bio has a 12-month low of $74.45 and a 12-month high of $236.17. The firm has a market cap of $8.73 billion, a P/E ratio of -22.62 and a beta of 2.17.
bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings results on Monday, May 7th. The biotechnology company reported ($2.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.01) by ($0.30). bluebird bio had a negative return on equity of 27.61% and a negative net margin of 857.55%. The company had revenue of $15.96 million for the quarter, compared to the consensus estimate of $5.85 million. During the same quarter last year, the company posted ($1.68) EPS. The company’s quarterly revenue was up 133.7% compared to the same quarter last year. analysts forecast that bluebird bio will post -9.1 EPS for the current fiscal year.
In other bluebird bio news, insider Philip D. Gregory sold 2,250 shares of the company’s stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $200.00, for a total value of $450,000.00. Following the completion of the transaction, the insider now owns 32,522 shares in the company, valued at approximately $6,504,400. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Davidson sold 22,000 shares of the company’s stock in a transaction on Monday, April 2nd. The shares were sold at an average price of $167.52, for a total value of $3,685,440.00. The disclosure for this sale can be found here. Insiders have sold 46,250 shares of company stock valued at $8,269,990 in the last quarter. 3.90% of the stock is currently owned by corporate insiders.
About bluebird bio
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.